Evidence map›Paper›PMID 33604348›Full record

ArticleFrontiers in medicine2021

YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial.

Weiping Liu, Yufu Li, Quanshun Wang, Hang Su, Kaiyang Ding, Yuerong Shuang, Sujun Gao, Dehui Zou, Hongmei Jing, Ye Chai and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Weiping LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Yufu LiDepartment of Hematology, Henan Cancer Hospital, Zhengzhou, China.
Quanshun WangDepartment of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
Hang SuDepartment of Lymphoma, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Kaiyang DingDepartment of Hematology, Anhui Provincial Cancer Hospital, Hefei, China.
Yuerong ShuangDepartment of Lymphoma & Hematology, Jiangxi Cancer Hospital, Nanchang, China.
Sujun GaoDepartment of Hematology, First Affiliated Hospital of Jilin University, Changchun, China.
Dehui ZouDepartment of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Hongmei JingDepartment of Hematology, Peking University Third Hospital, Beijing, China.
Ye ChaiDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou, China.
Yicheng ZhangDepartment of Hematology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lihong LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chunling WangDepartment of Hematology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China.
Hui LiuDepartment of Hematology, Beijing Hospital, Beijing, China.
Jinying LinDepartment of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Haiyan ZhuDepartment of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
Chen YaoDepartment of Medical Statistics, Peking University First Hospital, Beijing, China.
Xiaoyan YanPeking University Clinical Research Institute, Beijing, China.
Meixia ShangDepartment of Medical Statistics, Peking University First Hospital, Beijing, China.
Shufang WangHefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China.
Fengyuan ChangHefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China.
Xiaopei WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Jun ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Yuqin SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hematopoietic stem cell mobilizationlymphomanon-Hodgkinsafetytherapeuticstreatment outcome

Identifiers

PMID33604348
PMCPMC7884449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.